[PDF] Top 20 VIRAL BASED GENE THERAPY
Has 10000 "VIRAL BASED GENE THERAPY" found on our website. Below are the top 20 most common "VIRAL BASED GENE THERAPY".
VIRAL BASED GENE THERAPY
... for gene transfer into massive variety of ...the viral genome might not assimilate into the host genome, gene therapy via adenoviral vectors had precipitated harmful side results and flattens ... See full document
5
IL 12 based gene therapy in veterinary medicine
... rIL-12 therapy include elevated body temperature, headache, weakness and gastrointestinal toxicity (stomatitis, nausea and ...rIL-12 therapy even resulted in the death of treated patients ...the gene ... See full document
11
Gene therapy strategies for treating brain tumors: Retroviruses are still good candidates for therapeutic vectors
... the therapy, more than a 100 L of virus solution would need to be administrated into the brain, to ensure that 1 × 10 11 retroviruses are administered to the same number of cells, found in a tumor mass of a ... See full document
7
Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule
... the gene expres- sion of the GABA(A) receptor was studied in the spinal cord tissue of all treated animals because the exposure to BDNF induces a reduction in postsynaptic GABA(A) receptor number in cultured ... See full document
16
Advanced therapies for the treatment of hemophilia: future perspectives
... cell therapy and gene therapy —based on viral (lentiviral and adeno- associated) vectors with improved transfection efficacy and immunogenic properties, or non-viral vectors— may ... See full document
9
Survivin a radiogenetic promoter for glioblastoma viral gene therapy independently from CArG motifs
... reporter gene, a kind gift of Rob- ert ...galactosidase gene, provided by De-chu Tang, university of Alabama at Bir- mingham, Birmingham, AL) driven by different promot- ers; ...constructed based on ... See full document
11
Gene therapy for carcinoma of the breast: Pro apoptotic gene therapy
... cell-specific gene delivery in the loco- regional ...of gene transfer may be stricter, given the lack of firm evidence for a useful bystander effect mediated by pro-apoptotic interventions, perhaps with the ... See full document
13
Constitutive and inducible co-expression systems for non-viral osteoinductive gene therapy
... for gene transfer efficacy estimation based on luciferase expression (61 % positive, 8/13 animals) and bone formation (46 %, 6/13 animals) demonstrated fair gene transfer efficacies and the ... See full document
19
Improved osteogenic vector for non-viral gene therapy
... enhanced gene expression in our study is assumed to be based on the subsequent insertion of an artificial intron into the coding region of the ...BMP-2 gene was replaced with the respective secretion ... See full document
14
A novel gene based therapy for galaucoma:from discovery to preclinical development
... Were this work to be repeated or redesigned, a greater focus would be put on dose-response of both MMP-3 quantification in the AH and viral transduction and expression of MMP-3 for a number of reasons. Endogenous ... See full document
321
Delivery systems of CRISPR/Cas9-based cancer gene therapy
... cancer therapy due to their ability to preferentially infect cancer cells, exploited in the commonly called oncolytic therapy ...their viral parental structure while gRNA and Cas9 could be easily ... See full document
9
THE USE OF VIRAL VECTORS IN GENE TRANSFER THERAPY
... Gene therapy is strategy based on using genes as pharmaceuticals. Gene therapy is a treatment that involves altering the genes inside body's cells to stop ...disease. Gene ... See full document
6
Gene Therapy, Early Promises, Subsequent Problems, and Recent Breakthroughs
... are based on human immunodeficiency virus-1 (HIV-1), non-human immunodeficiency (SIV), or feline immunodeficiency ...stable gene transfer tool to various cells like stem ...various viral genetic ... See full document
7
Hepatitis C Virus Clearance after Discontinuation of Pegylated Interferon Alpha-2a Monotherapy in a Child
... his viral load was high (1400,000 ...of therapy, the patient’s serum HCV RNA status became positive ...serum viral load increased to 100,000 ...antiviral therapy resulted in failure or ... See full document
5
The utility of the new generation of humanized mice to study HIV 1 infection: transmission, prevention, pathogenesis, and treatment
... Mice deficient in the recombinase activating genes 1 and 2 (Rag1 and Rag2, respectively) do not exhibit leaky production of T and B lymphocytes. The immune phe- notypes in Rag1 -/- and Rag2 -/- strains are similar ... See full document
19
DNA Vaccines: Regulatory Considerations and Safety Aspects
... Clinical development of DNA vaccines follows a sequence of phases and starts with a Phase I study (WHO, 2004; Klug et al., 2012). This aims to assess the immunogenic efficacy and safety of the vaccine. Studies are ... See full document
10
Systemic MV Gene Therapy Close to Clinical Trials for Several Neuromuscular Diseases
... of gene therapy clinical trials using adeno-associated viral (AAV) vectors, the majority were safety studies involving local intramuscular delivery; to date only one has involved systemic delivery, ... See full document
5
Urnauer, Sarah (2017): Improved synthetic gene delivery vehicles for advanced bioimaging-guided tumor-targeted application of the sodium iodide symporter (NIS) as theranostic gene. Dissertation, LMU München: Fakultät für Chemie und Pharmazie
... luciferase gene and pCpG-hCMV-NIS [39]; human NIS plasmid DNA driven by the human elongation factor 1α promotor and human cytomegalovirus enhancer element) were prepared by Plasmid Factory GmbH (Bielefeld, ... See full document
188
Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV 1 RNA levels
... tinuous viral load under the detection threshold (HIV RNA <40/20 copies/mL depending on assay version) after the initial six ...with viral blips, 111 out of 603 ...developed viral failure, ... See full document
9
New Gene Therapy Strategies for the Deletion of Exon 44 of Dystrophin Gene Based on Gene Editing by TALENs
... replacement therapy, there is no effective therapy for muscular dystrophy in conventional ...medication. Gene editing technology from the recently developed engineered nu- cleases such as TALENs has ... See full document
6
Related subjects